[Meta] the 503A rule is doing its job and people should stop complaining
the 503A rule is doing its job and people should stop complaining. Nothing about this affects the ranking maths, before anyone asks.
On concentration, which is where I see people actually get hurt.
A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.
Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
I will update this if the picture changes rather than quietly leaving it up.
best — the order this archive was captured in
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
What did the intake actually ask you?
Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
salt forms are the recurring argument and the answer is boring
[deleted]
compounded is not generic, there is no equivalence claim
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
Correcting my own comment: the shortage status changed in the interim, so the arrangement I described no longer applies.
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
Careful.
Agreed — and the follow-up question is what the beyond-use date is based on.
Correcting my own comment: the shortage status changed in the interim, so the arrangement I described no longer applies.
Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.
potency testing on the finished preparation is the thing to ask for
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
Is the compound still on the shortage list where you are?
Did they name the facility?
ask which facility, then ask for their testing
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
the label on a compounded vial is a legal document, read it
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
- 1Is the compound still on the shortage list where you are?7 comments in this branch · started by u/runa_grimaldi
- 2Same view. If the intake asked you nothing, the intake was a formality and…6 comments in this branch · started by u/zaid_grimaldi